NXGLW — NEXGEL, Inc.

NEXGEL (NXGLW) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.9 million, flat year-over-year and slightly higher sequentially.
• Gross Profit: $1.24 million, up from $1.16 million year-over-year; gross profit margin improved to 42.4% from 39.3%.
• Adjusted EBITDA Loss: Narrowed to $354,000 from $419,000 in Q2 and $500,000 in Q1.
• Net Loss: $653,000, compared to $693,000 in Q3 2024.
• Cash Position: Approximately $938,000 in cash and $920,000 in restricted cash related to non-dilutive financing from Stada.

2. Strategic Updates and Business Highlights

• Contract Manufacturing: Revenue of $907,000, stable year-over-year, driven by strong relationships, particularly with Cintas. Initial orders for new customers like iRhythm are expected to contribute positively.
• Consumer Products: Stable revenue with new product launches, including lip gloss and eczema solutions, anticipated to drive growth in Q4.
• Partnerships: Expanded collaboration with Stada, including a soft launch of a new digestive enzyme product in December 2025, supported by $1 million in financing.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipated record revenues for Q4, with a forecast of total 2025 revenues between $12 million and $12.5 million, contingent on strong holiday sales.
• Profitability Outlook: Management aims for adjusted EBITDA to approach breakeven by year-end, depending on consumer product performance.

4. Bad News, Challenges, or Points of Concern

• Logistical Delays: Some product launches were delayed due to customs issues, potentially impacting sales by an estimated $100,000 to $200,000.
• Flat Revenue Growth: Year-over-year revenue stagnation raises concerns about the company's ability to scale without new customer onboarding.
• AbbVie Partnership Uncertainty: Confusion regarding AbbVie's plans for a recycling device, with potential implications for future orders.

5. Notable Q&A Insights

• Logistical Delays: Adam Levy explained that delays were primarily due to customs issues, affecting the timing of product launches.
• Revenue Guidance Confidence: Management expressed confidence in achieving the upper end of revenue guidance due to expected strong performance in Q4, despite recent flat growth.
• Contract Manufacturing Pipeline: A robust order book and new customer onboarding are expected to support growth in the coming quarters.
• Cash Position: The company is well-positioned to fulfill orders and manage inventory effectively, with expectations for improved cash flow in Q4.

This summary captures the essential financial metrics, strategic initiatives, outlook, and challenges discussed during the earnings call, providing a balanced view of NEXGEL's current position and future prospects.